GlassScriptPhysician profile
Jane S Weston
NPI 1518083245
$6,329.35
in general payments reported to CMS, 2019-2025
12 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $287 · 2021: $243 · 2022: $3,655 · 2023: $206 · 2024: $380 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,321.01 | 2019-2022 | |
| Mentor Worldwide LLC | $480.39 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Galderma Laboratories, L.P. | $407.31 | 2019-2025 | |
| Motiva USA, LLC | $270.58 | 2024-2025 | |
| Kerecis Limited | $254.05 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Merz North America, INC. | $172.18 | 2019-2025 | |
| Musculoskeletal Transplant Foundation INC. | $128.22 | 2019-2022 | |
| Abbvie INC. | $121.24 | 2023-2025 | Botox |
| Sientra, INC. | $83.33 | 2019 | |
| Revance Therapeutics, INC. | $34.54 | 2025 | |
| Integra Lifesciences Corporation | $32.84 | 2025 | Integra, Surgimend, Omnigraft |
| Vertex Pharmaceuticals Incorporated | $23.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Weston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.